Supplementary Figure 8. Analysis of intracellular cytokine changes in antigen-specific or ConA driven response, data presented as a frequency difference normalized to healthy controls. (a, b) CD4⁺ and CD8⁺ T cell subsets from splenocytes of EAE animals treated in vivo daily from onset with vehicle, nalfurafine (0.01mg/kg) or U50,488 (1.6 mg/kg). (c, d) CD4⁺ and CD8⁺ T cell freq from splenocytes of MOG35-55 immunized animals to day 28, and treated with vehicle (0.01% DMSO), nalfurafine (50 nM) or U50,488 (1 μM) for 72 hours alongside stimulations. (e, f) Analysis of CD4⁺ and CD8⁺ T cell intracellular IL-10 following in vivo KOR agonist treatment as MFI. (g) CD8⁺ T cell intracellular IL-17A (as frequency of parent, CD8⁺) following in vivo KOR agonist treatment (h) CD8⁺ T cell intracellular IL-17A (as frequency of parent, CD8⁺) following in vitro KOR agonist treatment, *P<0.05, ***P<0.001 by 1-way ANOVA with Holm-Sidak’s multiple comparison test. Data are mean ± SEM.